Ipsen S.A. (IPN.PA)

103,00 0,00 (0,00 %) À la clôture : 05:35PM CEST

Ipsen S.A.

65 Quai Georges Gorse
Cedex
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers—Specialty & Generic
Employés à temps plein: 5 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. David Loew	MD, CEO & Director	2,3M	S.O.	1967
Mr. Aymeric Le Chatelier	Exec. VP & Group CFO	S.O.	S.O.	1969
Dr. Aidan Murphy Ph.D.	Exec. VP of Technical Operations	S.O.	S.O.	1966
Mr. Craig Marks	Vice-Pres of Investor Relations	S.O.	S.O.	S.O.
Mr. Francois Garnier	Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer	S.O.	S.O.	1962
Ms. Gwenan White	Exec. VP of Communications & Public Affairs	S.O.	S.O.	S.O.
Mr. Regis Mulot	Exec. VP & Chief HR Officer	S.O.	S.O.	1966
Ms. Dominique Bery	Head of Nordics & Baltics	S.O.	S.O.	1971
Dr. Yan Moore M.D.	Sr. VP & Head of Oncology Therapeutic Area	S.O.	S.O.	1967
Dr. Alexander McEwan	Vice-Pres & Head of Radiopharmaceuticals	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Ipsen S.A. en date du 1 mars 2023 est 9. Les scores principaux sont Audit : 6; Société : 9; Droits des actionnaires : 7; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.